A significant clinical trial is underway at King's College Hospital NHS Foundation Trust, offering potential new avenues for managing Parkinson's Disease symptoms. The international ARISE trial is examining the efficacy of an oral drug, known as solengepras (CVN424), in addressing movement, balance, and coordination difficulties experienced by individuals with the condition.
The study focuses on an overactive brain receptor believed to contribute to the characteristic symptoms of Parkinson's, such as stiffness, slowness, unsteadiness, and tremors. Scientists are investigating whether solengepras (CVN424) can modulate this overactivity, thereby aiding patients in better symptom control.
“"The treatment and care that gives me my quality of life would not exist without decades of research, and so it feels extremely rewarding to be part of a trial that could improve the lives of Parkinson’s patients years in the future. By taking part in research, I have had the opportunity to learn so much about Parkinson’s Disease, and what I can do to make life easier and more enjoyable. While I do not yet know whether I received solengepras (CVN424) or a placebo, I look forward to the outcome of the trial, with the hope that a new treatment for Parkinson’s may be on the horizon."
Caroline Thomson, who has lived with Parkinson's Disease for eight years and is participating in the trial, expressed her gratitude for the opportunity to contribute to future medical advancements. She highlighted the importance of research in maintaining her quality of life and her anticipation for the trial's results.
Dr Mubasher Qamar, Senior Movement Disorder and Neurology Clinical and Research Fellow at King's, commented on the wide-ranging impact of Parkinson's Disease on patients' quality of life, including motor symptoms like tremor, slowness, and stiffness. He noted that as the condition progresses, existing treatments can become less effective, leading to unpredictable 'motor fluctuations'.
This Phase 3 study, involving 341 participants across the US, Europe, the UK, and Australia, aims to determine if solengepras (CVN424) can improve these motor fluctuations. Dr Qamar proudly stated that King's was the highest recruiting site in the UK for the ARISE study, contributing to its reaccreditation as a Parkinson's Foundation Centre of Excellence. He also extended thanks to the participants and the National Institute for Health and Care Research (NIHR) King's Clinical Research Facility for their crucial role.
Results from the ARISE Phase 3 study are anticipated later this year.
